Ken Griffin T2 Biosystems, Inc. Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
SELL
$0.09 - $565.0 $8,824 - $55.4 Million
-98,054 Reduced 33.21%
197,166 $22,000
Q2 2022

Aug 15, 2022
SELL
$0.15 - $0.54 $8,650 - $31,141
-57,670 Reduced 16.34%
295,220 $48,000
Q1 2022

May 16, 2022
BUY
$0.36 - $0.57 $22,935 - $36,315
63,711 Added 22.03%
352,890 $185,000
Q4 2021

Feb 14, 2022
BUY
$0.46 - $0.94 $71,138 - $145,370
154,649 Added 114.96%
289,179 $150,000
Q3 2021

Nov 15, 2021
SELL
$0.86 - $1.21 $43,721 - $61,515
-50,839 Reduced 27.43%
134,530 $123,000
Q2 2021

Aug 16, 2021
SELL
$1.04 - $1.69 $85,999 - $139,749
-82,692 Reduced 30.85%
185,369 $220,000
Q1 2021

May 17, 2021
BUY
$1.32 - $3.79 $252,533 - $725,076
191,313 Added 249.27%
268,061 $434,000
Q3 2020

Nov 16, 2020
SELL
$1.15 - $2.1 $141,163 - $257,777
-122,751 Reduced 61.53%
76,748 $104,000
Q2 2020

Aug 14, 2020
SELL
$0.48 - $1.67 $20,883 - $72,656
-43,507 Reduced 17.9%
199,499 $253,000
Q1 2020

May 15, 2020
BUY
$0.28 - $1.23 $55,537 - $243,969
198,349 Added 444.16%
243,006 $158,000
Q4 2019

Feb 14, 2020
BUY
$0.96 - $2.94 $28,178 - $86,297
29,353 Added 191.8%
44,657 $52,000
Q3 2019

Nov 14, 2019
SELL
$0.58 - $3.01 $12,635 - $65,572
-21,785 Reduced 58.74%
15,304 $38,000
Q2 2019

Aug 14, 2019
SELL
$1.47 - $3.16 $3,369 - $7,242
-2,292 Reduced 5.82%
37,089 $62,000
Q4 2018

Feb 14, 2019
BUY
$2.98 - $6.86 $6,812 - $15,681
2,286 Added 6.16%
39,381 $118,000
Q3 2018

Nov 13, 2018
BUY
$5.36 - $7.83 $100,644 - $147,023
18,777 Added 102.51%
37,095 $0
Q2 2018

Aug 10, 2018
BUY
$5.97 - $9.58 $109,358 - $175,486
18,318 New
18,318 $0

About T2 Biosystems, Inc.

TTOO Quotes by TradingView
  • Ticker TTOO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 7,050,850
  • Market Cap $15.9M
  • Description
  • T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fl...
More about TTOO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email